Atirmociclib

Phase 2Small molecule

Pfizer

Atirmociclib is one of 52 small molecule programs targeting Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Advanced Breast CancerRecruiting

Hepatic ImpairmentNot yet recruiting

Advanced CancerActive, not recruiting

Breast CancerPhase 1/Phase 2

Active, not recruiting

Advanced Breast CancerPhase 2

Recruiting

Hepatic ImpairmentPhase 1

Not yet recruiting

Advanced CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Atirmociclib

Pfizer

Phase 2

2 3

Gemzar

GGynecologic Oncology Group

Preclinical

22 4

Lexiscan

Astellas

Preclinical

1 5

Adenocard

Astellas

Preclinical

1 6

Zolymbus

AbbVie

Preclinical

1 7

Vfend

PPrism Pharmaceuticals

Systemic Therapy

1 9

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 10

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Active, not recruiting

Advanced Cancer

NCT06239467

Phase 1Not yet recruiting

Hepatic Impairment

NCT07677358

Q4 2027

Phase 2Recruiting

Advanced Breast Cancer

NCT07427394

Q1 2028

Phase 1Recruiting

Breast Cancer

NCT05508906

Q3 2030

Phase 1/2Recruiting

Breast Cancer

NCT03424005

Clinical

Trials by Indication[1]

Breast Cancer2 trials

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

Recruiting· Roche logo

Roche·Phase 1/2·NCT03424005·792 enrolled

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Recruiting·OOlema Pharmaceuticals, Inc.·Phase 1·NCT05508906·190 enrolled

ART1 trial

Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy Participants

Recruiting· Pfizer logo

Pfizer·Phase 1·NCT07215078·72 enrolled

Advanced Breast Cancer1 trial

A Phase IIa, Open-label Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Camizestrant in Combination With Atirmociclib in Participants With ER-positive, HER2-negative Advanced Breast Cancer (SERENA-1b)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT07427394·24 enrolled

Advanced Cancer1 trial

PIKture-01: First-in-Human Study of the PI3KαH1047R Mutant-Selective Inhibitor OKI-219 as Monotherapy in Participants With Advanced Solid Tumors and as Part of Combination Therapy in Participants With Advanced Breast Cancer

Active, not recruiting·OOnKure, Inc.·Phase 1·NCT06239467·200 enrolled

Hepatic Impairment1 trial

A PHASE 1, NON-RANDOMIZED, OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP STUDY TO COMPARE THE PHARMACOKINETICS OF ATIRMOCICLIB IN ADULT PARTICIPANTS WITH VARYING DEGREES OF HEPATIC IMPAIRMENT RELATIVE TO PARTICIPANTS WITH NORMAL HEPATIC FUNCTION

Not yet recruiting· Pfizer logo

Pfizer·Phase 1·NCT07677358·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Atirmociclib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Atirmociclib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Atirmociclib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Pfizer

Atirmociclib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Q1 2028

Q3 2030

Trials by Indication[1]

Breast Cancer2 trials

ART1 trial

Advanced Breast Cancer1 trial

Advanced Cancer1 trial

Hepatic Impairment1 trial

References

Drug Info

Quick Facts

Related News